CS17291A2 - Recombinantly prepared blood factors, method of stated blood factors expression and also recombinants of virus of vaccine that is used in stated process - Google Patents

Recombinantly prepared blood factors, method of stated blood factors expression and also recombinants of virus of vaccine that is used in stated process Download PDF

Info

Publication number: CS17291A2
Authority: CS; Czechoslovakia
Prior art keywords: plasmid; vaccinia virus; promoter; factor; cells
Prior art date: 1990-01-26

Application number

CS91172A

Other languages

Czech (cs)

English (en)

Inventor

Falko-Gunter Dr Falkner

Ross T A Macgillivray

Walter Dr Bodemer

Friedrich Ing Scheiflinger

Johann Dr Eibl

Friedrich Prof Ing Dorner

Original Assignee

Immuno Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-01-26

Filing date

1991-01-25

Publication date

1991-09-15

1991-01-25 Application filed by Immuno Ag filed Critical Immuno Ag

1991-09-15 Publication of CS17291A2 publication Critical patent/CS17291A2/cs

Links

230000014509 gene expression Effects 0.000 title claims abstract description 60
229960000182 blood factors Drugs 0.000 title claims abstract description 34
238000000034 method Methods 0.000 title claims abstract description 23
230000008569 process Effects 0.000 title claims abstract description 8
241000700605 Viruses Species 0.000 title claims description 47
229960005486 vaccine Drugs 0.000 title description 12
241000700618 Vaccinia virus Species 0.000 claims abstract description 59
230000000890 antigenic effect Effects 0.000 claims abstract description 5
210000004027 cell Anatomy 0.000 claims description 95
108010094028 Prothrombin Proteins 0.000 claims description 77
239000013612 plasmid Substances 0.000 claims description 72
229940039716 prothrombin Drugs 0.000 claims description 68
102100027378 Prothrombin Human genes 0.000 claims description 67
239000002773 nucleotide Substances 0.000 claims description 55
125000003729 nucleotide group Chemical group 0.000 claims description 53
108090000623 proteins and genes Proteins 0.000 claims description 50
102000004169 proteins and genes Human genes 0.000 claims description 29
108020004414 DNA Proteins 0.000 claims description 26
239000002299 complementary DNA Substances 0.000 claims description 19
206010046865 Vaccinia virus infection Diseases 0.000 claims description 17
208000007089 vaccinia Diseases 0.000 claims description 16
230000001419 dependent effect Effects 0.000 claims description 13
238000003780 insertion Methods 0.000 claims description 12
230000037431 insertion Effects 0.000 claims description 12
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 12
239000006228 supernatant Substances 0.000 claims description 12
229930003448 Vitamin K Natural products 0.000 claims description 11
208000015181 infectious disease Diseases 0.000 claims description 11
235000019168 vitamin K Nutrition 0.000 claims description 11
239000011712 vitamin K Substances 0.000 claims description 11
150000003721 vitamin K derivatives Chemical class 0.000 claims description 11
229940046010 vitamin k Drugs 0.000 claims description 11
238000010367 cloning Methods 0.000 claims description 10
238000001727 in vivo Methods 0.000 claims description 10
108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
108010076504 Protein Sorting Signals Proteins 0.000 claims description 8
150000001413 amino acids Chemical class 0.000 claims description 8
229920001184 polypeptide Polymers 0.000 claims description 8
108090000765 processed proteins & peptides Proteins 0.000 claims description 8
102000004196 processed proteins & peptides Human genes 0.000 claims description 8
238000004113 cell culture Methods 0.000 claims description 7
210000003292 kidney cell Anatomy 0.000 claims description 7
108020004440 Thymidine kinase Proteins 0.000 claims description 6
238000003776 cleavage reaction Methods 0.000 claims description 6
230000007017 scission Effects 0.000 claims description 6
108020004705 Codon Proteins 0.000 claims description 5
239000003550 marker Substances 0.000 claims description 5
108091008146 restriction endonucleases Proteins 0.000 claims description 5
102000006601 Thymidine Kinase Human genes 0.000 claims description 4
102100023804 Coagulation factor VII Human genes 0.000 claims description 3
108010023321 Factor VII Proteins 0.000 claims description 3
101800004937 Protein C Proteins 0.000 claims description 3
102000017975 Protein C Human genes 0.000 claims description 3
101800001700 Saposin-D Proteins 0.000 claims description 3
229940012413 factor vii Drugs 0.000 claims description 3
238000002744 homologous recombination Methods 0.000 claims description 3
230000006801 homologous recombination Effects 0.000 claims description 3
210000005229 liver cell Anatomy 0.000 claims description 3
229960000856 protein c Drugs 0.000 claims description 3
108010014172 Factor V Proteins 0.000 claims description 2
108010054218 Factor VIII Proteins 0.000 claims description 2
102000001690 Factor VIII Human genes 0.000 claims description 2
108010014173 Factor X Proteins 0.000 claims description 2
108010080865 Factor XII Proteins 0.000 claims description 2
102000000429 Factor XII Human genes 0.000 claims description 2
108010071289 Factor XIII Proteins 0.000 claims description 2
108010051456 Plasminogen Proteins 0.000 claims description 2
229960000301 factor viii Drugs 0.000 claims description 2
229940012426 factor x Drugs 0.000 claims description 2
229940012444 factor xiii Drugs 0.000 claims description 2
239000012510 hollow fiber Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
108010047303 von Willebrand Factor Proteins 0.000 claims description 2
102100036537 von Willebrand factor Human genes 0.000 claims description 2
229960001134 von willebrand factor Drugs 0.000 claims description 2
238000012258 culturing Methods 0.000 claims 2
-1 FactorIX Proteins 0.000 claims 1
102000013566 Plasminogen Human genes 0.000 claims 1
229940096437 Protein S Drugs 0.000 claims 1
102000029301 Protein S Human genes 0.000 claims 1
108010066124 Protein S Proteins 0.000 claims 1
241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
230000002485 urinary effect Effects 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 5
230000001323 posttranslational effect Effects 0.000 abstract description 2
230000010473 stable expression Effects 0.000 abstract 1
239000012634 fragment Substances 0.000 description 25
235000018102 proteins Nutrition 0.000 description 25
230000003612 virological effect Effects 0.000 description 19
238000010276 construction Methods 0.000 description 14
239000013598 vector Substances 0.000 description 12
239000000523 sample Substances 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
108090000190 Thrombin Proteins 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
210000003734 kidney Anatomy 0.000 description 9
229960004072 thrombin Drugs 0.000 description 9
230000028327 secretion Effects 0.000 description 8
238000012360 testing method Methods 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
108091081024 Start codon Proteins 0.000 description 7
239000003114 blood coagulation factor Substances 0.000 description 7
230000006798 recombination Effects 0.000 description 7
238000005215 recombination Methods 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
229940039715 human prothrombin Drugs 0.000 description 6
238000011534 incubation Methods 0.000 description 6
230000004481 post-translational protein modification Effects 0.000 description 6
230000010076 replication Effects 0.000 description 6
102000053602 DNA Human genes 0.000 description 5
101000651439 Homo sapiens Prothrombin Proteins 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
238000002741 site-directed mutagenesis Methods 0.000 description 5
108010039209 Blood Coagulation Factors Proteins 0.000 description 4
102000015081 Blood Coagulation Factors Human genes 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
241000710188 Encephalomyocarditis virus Species 0.000 description 4
102000003886 Glycoproteins Human genes 0.000 description 4
108090000288 Glycoproteins Proteins 0.000 description 4
108020004682 Single-Stranded DNA Proteins 0.000 description 4
239000000872 buffer Substances 0.000 description 4
210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
239000000499 gel Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
238000012986 modification Methods 0.000 description 4
238000012545 processing Methods 0.000 description 4
229960003766 thrombin (human) Drugs 0.000 description 4
229940088594 vitamin Drugs 0.000 description 4
229930003231 vitamin Natural products 0.000 description 4
235000013343 vitamin Nutrition 0.000 description 4
239000011782 vitamin Substances 0.000 description 4
150000003722 vitamin derivatives Chemical class 0.000 description 4
241000699800 Cricetinae Species 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000021523 carboxylation Effects 0.000 description 3
238000006473 carboxylation reaction Methods 0.000 description 3
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
230000010354 integration Effects 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
238000013519 translation Methods 0.000 description 3
238000001262 western blot Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000282552 Chlorocebus aethiops Species 0.000 description 2
101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 description 2
101000658546 Escherichia coli Type I restriction enzyme EcoEI endonuclease subunit Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
241001494479 Pecora Species 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
229960004222 factor ix Drugs 0.000 description 2
230000006870 function Effects 0.000 description 2
101150106093 gpt gene Proteins 0.000 description 2
230000012010 growth Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
239000000203 mixture Substances 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
229940079938 nitrocellulose Drugs 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
210000003501 vero cell Anatomy 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000271566 Aves Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000195940 Bryophyta Species 0.000 description 1
101100243401 Caenorhabditis elegans pept-3 gene Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
230000009946 DNA mutation Effects 0.000 description 1
241000701832 Enterobacteria phage T3 Species 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101150039660 HA gene Proteins 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
101500025568 Homo sapiens Saposin-D Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
241000819999 Nymphes Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102100038124 Plasminogen Human genes 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000831652 Salinivibrio sharmensis Species 0.000 description 1
102000040739 Secretory proteins Human genes 0.000 description 1
108091058545 Secretory proteins Proteins 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
206010042566 Superinfection Diseases 0.000 description 1
101150003725 TK gene Proteins 0.000 description 1
108010079274 Thrombomodulin Proteins 0.000 description 1
102100026966 Thrombomodulin Human genes 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000007820 coagulation assay Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
108091005606 gamma-carboxylated proteins Proteins 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
229940094991 herring sperm dna Drugs 0.000 description 1
229940100689 human protein c Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000003999 initiator Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
238000005457 optimization Methods 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000007030 peptide scission Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
235000019175 phylloquinone Nutrition 0.000 description 1
239000011772 phylloquinone Substances 0.000 description 1
MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
229960001898 phytomenadione Drugs 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
238000007781 pre-processing Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000004575 stone Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Hematology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Auxiliary Devices For Machine Tools (AREA)
Gear Processing (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CS91172A 1990-01-26 1991-01-25 Recombinantly prepared blood factors, method of stated blood factors expression and also recombinants of virus of vaccine that is used in stated process CS17291A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP90101623		1990-01-26

Publications (1)

Publication Number	Publication Date
CS17291A2 true CS17291A2 (en)	1991-09-15

Family

ID=8203546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS91172A CS17291A2 (en)	1990-01-26	1991-01-25	Recombinantly prepared blood factors, method of stated blood factors expression and also recombinants of virus of vaccine that is used in stated process

Country Status (12)

Country	Link
EP (1)	EP0512011B1 (es)
JP (1)	JP2549224B2 (es)
AT (1)	ATE103982T1 (es)
CA (1)	CA2073859A1 (es)
CS (1)	CS17291A2 (es)
DE (2)	DE69101634T4 (es)
DK (1)	DK0512011T3 (es)
ES (1)	ES2052368T3 (es)
FI (1)	FI923347A7 (es)
HU (1)	HUT63459A (es)
NO (1)	NO922953L (es)
WO (1)	WO1991011519A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69229390T2 (de) *	1991-08-26	1999-11-11	Immuno Ag, Wien	Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
AU683834B2 (en) *	1991-12-31	1997-11-27	Zymogenetics Inc.	Methods for producing thrombin
US5527692A (en) *	1991-12-31	1996-06-18	Zymogenetics, Inc.	Methods for producing thrombin
AU1096595A (en) *	1993-11-12	1995-05-29	Gilead Sciences, Inc.	Thrombin mutants
US7060484B1 (en)	1993-11-12	2006-06-13	Gilead Sciences, Inc.	Polypeptides and coagulation therapy
DE4430204A1 (de) *	1994-08-26	1996-02-29	Behringwerke Ag	Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
AT403167B (de) *	1994-11-14	1997-11-25	Immuno Ag	Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
AT404357B (de) *	1995-06-13	1998-11-25	Immuno Ag	Prothrombin-derivate
DK0796623T3 (da) *	1996-03-20	2005-08-01	Baxter Ag	Farmaceutisk præparat til behandling af blodkoagulationslidelser
US7247708B2 (en)	1997-10-23	2007-07-24	Regents Of The University Of Minnesota	Modified vitamin K-dependent polypeptides
US6747003B1 (en)	1997-10-23	2004-06-08	Regents Of The University Of Minnesota	Modified vitamin K-dependent polypeptides
CA2739933A1 (en)	2000-02-11	2001-08-16	Bayer Healthcare Llc	Factor vii or viia-like molecules
EP1136553A1 (en) *	2000-03-22	2001-09-26	Octagene GmbH	Production of recombinant blood clotting factors in human cell lines
EE200200538A (et) *	2000-03-22	2004-04-15	Octagene Gmbh	Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides
US7220837B1 (en)	2000-04-28	2007-05-22	Regents Of The University Of Minnesota	Modified vitamin K-dependent polypeptides
US7812132B2 (en)	2000-04-28	2010-10-12	Regents Of The University Of Minnesota	Modified vitamin K-dependent polypeptides
US20030211094A1 (en)	2001-06-26	2003-11-13	Nelsestuen Gary L.	High molecular weight derivatives of vitamin k-dependent polypeptides
WO2003093465A1 (en)	2002-04-30	2003-11-13	Maxygen Holdings Ltd.	FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
CA2519873C (en)	2003-03-20	2012-12-18	Maxygen Holdings Ltd.	Fvii or fviia variants
RU2373282C2 (ru)	2003-06-19	2009-11-20	Байер Хелткэр Ллк	ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
JP6245299B2 (ja) *	2016-04-27	2017-12-13	バクスアルタゲーエムベーハー	組換え安定細胞クローン、その産生およびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8508845D0 (en) *	1985-04-04	1985-05-09	Hoffmann La Roche	Vaccinia dna
AU8339187A (en) *	1986-11-17	1988-06-16	New England Medical Center Hospitals, Inc., The	Enhancing gamma-carboxylation of recombinant vitamin k-dependent proteins
EP0380508A4 (en) *	1987-05-18	1991-04-03	Integrated Genetics, Inc.	Improved protein c molecules and method for making and activating same
FR2619314B1 (fr) *	1987-08-11	1990-06-15	Transgene Sa	Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
DE3813093A1 (de) *	1988-04-19	1989-11-09	Immuno Ag	Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
FR2638643B1 (fr) *	1988-11-09	1991-04-12	Transgene Sa	Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants

1991
- 1991-01-24 DE DE69101634T patent/DE69101634T4/de not_active Expired - Lifetime
- 1991-01-24 AT AT91903050T patent/ATE103982T1/de not_active IP Right Cessation
- 1991-01-24 DE DE91903050A patent/DE69101634D1/de not_active Expired - Fee Related
- 1991-01-24 JP JP3503086A patent/JP2549224B2/ja not_active Expired - Lifetime
- 1991-01-24 EP EP91903050A patent/EP0512011B1/en not_active Expired - Lifetime
- 1991-01-24 WO PCT/EP1991/000139 patent/WO1991011519A1/en not_active Ceased
- 1991-01-24 DK DK91903050.2T patent/DK0512011T3/da active
- 1991-01-24 FI FI923347A patent/FI923347A7/fi not_active Application Discontinuation
- 1991-01-24 HU HU922435A patent/HUT63459A/hu unknown
- 1991-01-24 CA CA002073859A patent/CA2073859A1/en not_active Abandoned
- 1991-01-24 ES ES91903050T patent/ES2052368T3/es not_active Expired - Lifetime
- 1991-01-25 CS CS91172A patent/CS17291A2/cs unknown
1992
- 1992-07-24 NO NO92922953A patent/NO922953L/no unknown

Also Published As

Publication number	Publication date
EP0512011A1 (en)	1992-11-11
FI923347L (fi)	1992-07-23
NO922953L (no)	1992-09-04
HUT63459A (en)	1993-08-30
DE69101634T4 (de)	1994-12-01
DE69101634T2 (de)	1994-08-18
WO1991011519A1 (en)	1991-08-08
CA2073859A1 (en)	1991-07-27
JPH05507401A (ja)	1993-10-28
DK0512011T3 (da)	1994-05-09
DE69101634D1 (de)	1994-05-11
ES2052368T3 (es)	1994-07-01
FI923347A0 (fi)	1992-07-23
ATE103982T1 (de)	1994-04-15
FI923347A7 (fi)	1992-07-23
HU9202435D0 (en)	1992-10-28
JP2549224B2 (ja)	1996-10-30
NO922953D0 (no)	1992-07-24
EP0512011B1 (en)	1994-04-06

Publication	Publication Date	Title
CS17291A2 (en)	1991-09-15	Recombinantly prepared blood factors, method of stated blood factors expression and also recombinants of virus of vaccine that is used in stated process
CA2076839C (en)	2007-06-12	Direct molecular cloning of a modified eukaryotic cytoplasmic dna virus genome
AU625584B2 (en)	1992-07-16	Recombinant poxvirus host selection system
US5225336A (en)	1993-07-06	Recombinant poxvirus host range selection system
KR101005630B1 (ko)	2011-01-05	수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는재조합 수두 바이러스
Tomalski et al.	1991	A baculovirus homolog of aCu/Znsuperoxide dismutase gene
Banerjea et al.	1988	High-level synthesis of biologically active reovirus protein σ1 in a mammalian expression vector system
JPH05192165A (ja)	1993-08-03	組換え鶏痘ウイルス
JP2936201B2 (ja)	1999-08-23	ヒト第▲ｉｘ▼因子または類似の蛋白質をコードするｄｎａ配列、発現ベクター、形質転換された細胞、第▲ｉｘ▼因子の製造方法および得られた対応する生成物
US5445953A (en)	1995-08-29	Direct molecular cloning of a modified poxvirus genome
JPH0365191A (ja)	1991-03-20	スフェロイジン単離ｄｎａおよび組み換え昆虫ポックスウィルス発現ベクター
Li et al.	1988	Expression of the M gene of vesicular stomatitis virus cloned in various vaccinia virus vectors
WO1990012101A1 (en)	1990-10-18	Vaccinia vectors, vaccinia genes and expression products thereof
Mathur et al.	1996	Expression of L protein of vesicular stomatitis virus Indiana serotype from recombinant baculovirus in insect cells: requirement of a host factor (s) for its biological activity in vitro
Falkner et al.	1992	High level expression of active human prothrombin in a vaccina virus expression system
US10208101B2 (en)	2019-02-19	Recombinant fibrinogen high-production line and method for producing same
Takehara et al.	1994	Secretion of recombinant rat annexin 5 by insect cells in a baculovirus expression system
CA2515166C (en)	2007-05-15	Direct molecular cloning of a modified eukaryotic cytoplasmic dna virus genome
CA2558864C (en)	2009-12-08	Direct molecular cloning of a modified eukaryotic cytoplasmic dna virus genome
Himly et al.	1998	Defective vaccinia virus as a biologically safe tool for the overproduction of recombinant human secretory proteins
CA2617830C (en)	2010-04-06	Direct molecular cloning of a modified eukaryotic cytoplasmic dna virus genome
SK277781B6 (en)	1995-01-12	Peptides and polypeptides, vaccines and nucleous acid
IE60641B1 (en)	1994-07-27	Human protein s, a plasma protein regulator of hemostasis
JPH02156883A (ja)	1990-06-15	組み換えワクチニアウイルス
HK1076836B (en)	2009-09-04	Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)